APTO-253
- Generic Name
- APTO-253
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H14FN5
- CAS Number
- 916151-99-0
- Unique Ingredient Identifier
- WB59MRW00U
- Associated Conditions
- -
- Associated Therapies
- -
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Aptose Biosciences Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02267863
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Rochester; Wilmot Cancer Institute Clinical Trials Office, Rochester, New York, United States
🇺🇸Ochsner Cancer Institute, New Orleans, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath